AlphaStocks
6.4
Consider Buy

HAEMONETICS CORP (HAE)

Health Care / Health Care Supplies

S&P MidCap 400

$56.22

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 5 of 5 models — high confidence

#192out of 1127 in Health Care

Is HAEMONETICS CORP a Good Investment in 2026?

HAEMONETICS CORP (HAE) scores 6.4 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Buffett model rates HAEMONETICS CORP as Strong. However, the Graham model rates it Caution — 56% above fair value. HAEMONETICS CORP currently trades below its estimated fair value of $84, suggesting potential upside. HAEMONETICS CORP ranks #192 out of 1127 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E17.0ROE19.4Market Cap3B

Estimated Fair Value

$84.2733% below

Fair value above market price. EPS grew 45% year-over-year. P/E of 17x is moderate for this quality level.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

6/9

Buffett

Strong

Business quality & competitive moat

Graham

Caution

56% above fair value

Lynch

Neutral

High PEG — growth premium · Slow Grower

Greenblatt

Attractive

Top half (rank 32%)

Frequently Asked Questions

Is HAEMONETICS CORP (HAE) a good investment?
Based on AlphaStocks' composite analysis, HAEMONETICS CORP (HAE) scores 6.4 out of 10, earning a Consider Buy rating. This is a middle-of-the-pack score with no strong signal either way. Fair value above market price. EPS grew 45% year-over-year. P/E of 17x is moderate for this quality level.
What is HAEMONETICS CORP's Piotroski F-Score?
HAEMONETICS CORP's Piotroski F-Score status is Attractive. The raw score is 6/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is HAE overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $84, HAE appears undervalued. The stock currently trades 33% below its estimated fair value. Fair value above market price. EPS grew 45% year-over-year. P/E of 17x is moderate for this quality level.
How does HAE compare to other Health Care stocks?
HAEMONETICS CORP ranks #192 out of 1127 stocks in the Health Care sector, placing it in the top 17% of its sector by composite score. This is a strong position relative to sector peers.
What do investment models say about HAE?
AlphaStocks evaluates HAE using five proven investment models. Piotroski: Attractive; Buffett: Strong; Graham: Caution; Lynch: Neutral; Greenblatt Magic Formula: Attractive. These models are combined into a single composite score of 6.4/10.

Similar Stocks

PARRFTIAZN

Compare HAE with

HAE vs PARRHAE vs FTIHAE vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer